Serina Therapeutics (SER) Non-Current Debt (2019 - 2024)

Serina Therapeutics has disclosed Non-Current Debt across 6 years of filings, most recently posting $693000.0 for Q3 2024.

• In Q3 2024, Non-Current Debt changed 0.0% year-over-year to $693000.0; the TTM figure through Sep 2024 stood at $693000.0 (changed 0.0% YoY), while the FY2022 annual figure was $10.5 million, up 72.85% from the prior year.
• Non-Current Debt came in at $693000.0 for Q3 2024 at Serina Therapeutics, roughly flat from $693000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $10.5 million in Q4 2022 to a low of $693000.0 in Q3 2023.
• Average Non-Current Debt over 5 years is $4.9 million, with a median of $5.3 million recorded in 2021.
• Year-over-year, Non-Current Debt surged 1520.42% in 2020 and plunged 93.12% in 2024.
• Over 5 years, Non-Current Debt stood at $3.9 million in 2020, then jumped by 55.44% to $6.1 million in 2021, then jumped by 72.85% to $10.5 million in 2022, then slumped by 93.39% to $693000.0 in 2023, then changed by 0.0% to $693000.0 in 2024.
• Per Business Quant data, the three most recent Non-Current Debt figures were $693000.0 in Q3 2024, $693000.0 in Q2 2024, and $693000.0 in Q1 2024.